natgillin/translations-raw huggingface dataset:
Samtidig administration af det antipsykotiske lægemiddel lurasidon og fosamprenavir/ritonavir (FPV / RTV) er kontraindiceret (se pkt. 
Co-administration of the antipsychotic medicinal product lurasidone and fosamprenavir/ritonavir (FPV/RTV) is contraindicated (see section 4.5).
Hvis du har spørgsmål til disse oplysninger:  Tal med lægen. 
If you have any questions about this information or the advice given: →Talk to your doctor.
Nukleosid/Nukleotid revers transkriptasehæmmere: 
Nucleoside / Nucleotide reverse transcriptase inhibitors:
Telzir kræver ingen særlige forholdsregler vedrørende opbevaringen. 
Telzir does not require any special storage conditions.
En resistensmutation forekom i alle 3 isolater: henholdsvis K20K/R, I54I/L og I93I/L. 
One resistance mutation was observed in each of 3 isolates: K20K/R, I54I/L and I93I/L respectively
Telzir oral suspension indeholder propyl- og methylparahydroxybenzoat. 
The Telzir oral suspension contains propyl and methyl parahydroxybenzoate.
Idet doserne anvendt i reproduktionsstudierne var lave, er den potentielle udviklingstoksicitet af Telzir ikke fuldstændigt klarlagt. 
In view of the low exposure in reproductive toxicity studies, the potential developmental toxicity of Telzir has not been fully determined.
Bivirkningerne havde som minimum moderat intensitet (grad 2 eller derover) hos mindst 1 % af patienterne og blev rapporteret af investigator som relateret til lægemidlet anvendt i studiet. 
Most of the adverse reactions below were reported from three large clinical studies in adults, where the adverse events were of at least moderate intensity (Grade 2 or more) occurring in at least 1% of patients and reported by investigators as being attributable to the medicinal products used in the studies.
Fosamprenavir var ikke mutagent eller genotoksisk i en række genetiske toksicitetsprøver foretaget in vivo og in vitro. 
Fosamprenavir was not mutagenic or genotoxic in a standard battery of in vitro and in vivo assays.
Ritonavir: Cmax  63 %* Ritonavir: AUC  45 %* * sammenlignet med historiske data 
Ritonavir: Cmax ↑ 63%* Ritonavir: AUC ↑ 45%* * compared to historical data
Samtidig brug af Telzir med ritonavir og fluticason eller andre glukokortikoider, som metaboliseres af CYP3A4, frarådes, med mindre de potentielle fordele ved behandlingen opvejer risikoen for systemiske bivirkninger forårsaget af kortikosteroider, herunder Cushings syndrom og binyrebarksuppression (se pkt. 
Concomitant use of Telzir with ritonavir and fluticasone or other glucocorticoids that are metabolised by CYP3A4 is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression (see section
• hvis du har en leversygdom. 
• If you have liver disease.
Det skal du vide, før du begynder at tage Telzir 
What you need to know before you take Telzir
Tabel 1 Effektresultat ved uge 48 i studiet ESS100732 (ART-naive patienter) 
Table 1 Efficacy Outcome at Week 48 in ESS100732 (ART-Naïve Patients)
Samtidig anvendelse frarådes. 
Concomitant use is not recommended.
Patienter med plasma hiv-1 RNA < 400 kopier/ml, snapshot analyse Median ændring fra baseline i CD4-celler (celler/μl), observeret analyse 
Patients with plasma HIV-1 RNA <400 copies/ml, Snapshot analysis Median change from baseline in CD4 cells
Telzir kan ikke forhindre dig i at smitte. 
Telzir will not stop you passing on HIV.
En klinisk signifikant stigning af levertransaminase forekom hos nogle personer. 
Clinically significant hepatic transaminase elevations occurred in some subjects.
Der er ikke udført studier, hvor Telzir/ritonavir tages sammen med anden hormonbehandling såsom hormonerstatning. 
No studies have been done on the use of Telzir/ritonavir with other hormonal therapies, such as hormone replacement therapy (HRT).
De hyppigst (> 5 % af behandlede voksne patienter) rapporterede bivirkninger med kombination af fosamprenavir/ritonavir var gastrointestinale reaktioner (kvalme, diarré, mavesmerter og opkastning) og hovedpine. 
The most frequently (> 5% of adult subjects treated) reported adverse reactions with fosamprenavir/ritonavir combination were gastrointestinal reactions (nausea, diarrhoea, abdominal pain and vomiting) and headache.
Den kliniske erfaring med fosamprenavir boosted med ritonavir er hovedsageligt baseret på to åbne studier, et studie udført hos antiretroviral-naive patienter (studie ESS100732), samt et studie hos antiretroviral-erfarne patienter (studie APV30003). 
Clinical experience with fosamprenavir boosted with ritonavir is mainly based on two open label studies, one in antiretroviral naïve patients (study ESS100732), and one study in antiretroviral experienced patients (study APV30003).
Antiviral aktivitet baseret på genotype/fænotype-resistens 
Antiviral activity according to genotypic/phenotypic resistance
Forekomsten af de endometriale fund var en smule højere sammenlignet med kontrolgruppen, men inden for normalen (background range) for hunrotter. 
The incidence of endometrial findings was slightly increased over concurrent controls, but within background range for female rats.
Dosisjustering vurderes unødvendig hos patienter med nedsat nyrefunktion (se pkt. 
No dose adjustment is considered necessary in patients with renal impairment (see section 5.2).
Der kan ikke gives doseringsanbefalinger for meget unge børn (børn < 2 år), og Telzir i kombination med ritonavir bør ikke anvendes til denne patientgruppe (se pkt. 
No dosing recommendations can be made for the very young (children < 2 years of age) and Telzir with ritonavir is not recommended for this patient population (see section 4.2).
Pædiatriske patienter bør tage den orale suspension med mad for at forbedre smag og komplians (se pkt. 
In paediatric patients, the oral suspension should be taken with food in order to aid palatability and assist compliance (see section 5.2).
Reduktionen af (R-) methadon (aktiv enantiomer) forventes ikke at være klinisk signifikant, men for en sikkerheds skyld skal patienterne overvåges for abstinenser. 
The decrease of (R-) methadone (active enantiomer) is not expected to be clinically significant.
Hos patienter, der tidligere er behandlet med proteasehæmmere (PI'er), bør valget af Telzir baseres på individuel testning af virusresistens og patientens tidligere behandling (se pkt. 
In protease inhibitor (PI) experienced patients, the choice of Telzir should be based on individual viral resistance testing and treatment history (see section 5.1).
ANTACIDA, HISTAMINH2-RECEPTORANTAGONISTER OG PROTONPUMPEHÆMMERE 
ANTACIDS, HISTAMINE H2 RECEPTOR ANTAGONIST AND PROTON-PUMP INHIBITORS
Der er ikke observeret klinisk signifikant interaktion. 
No clinically significant interaction is observed.
Toksiciteten forekom ved plasmakoncentrationer, som var lavere end plasmakoncentrationen hos mennesker ved behandling med fosamprenavir i kombination med ritonavir ved den anbefalede dosis. 
Toxicity was similar to that of amprenavir and occurred at amprenavir plasma exposure levels below human exposure after treatment with fosamprenavir in combination with ritonavir at the recommended dose.
Telzir i kombination med en lav dosis ritonavir anvendes sammen med anden antiretroviral medicin (”kombinationsbehandling”) til behandling af voksne, unge og børn fra 6 år, der har hiv. 
Telzir with low doses of ritonavir is used in combination with other anti-retroviral medicines (‘combination therapy') to treat adults, adolescents and children aged over 6 years infected with HIV.
ETIKET TIL FLASKE TIL ORAL SUSPENSION 
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL FOR ORAL SUSPENSION
Telzir skal anvendes i kombination med lave doser ritonavir og anden antiretroviral medicin. 
Telzir is to be taken in combination with low doses of ritonavir and other antiretroviral medicines.
Telzir må ikke blandes med andre lægemidler, hverken i sprøjten eller i flasken. 
Step by step instructions Do not mix Telzir with any other medicines in the bottle or the syringe.
Børn og unge bør tage Telzir oral suspension sammen med mad. 
Children and adolescents should take the Telzir oral suspension with food.
Alvorlige proteasemutationer opstået under behandling eller APV-forbundede mutationer blev set i virus isoleret fra 1 patient i APV29005 og 6 patienter fra APV20003. 
Treatment-emergent major protease or APV-associated mutations were observed in virus isolated from 1 patient in APV29005 and 6 patients from APV20003.
Tenofovirdisoproxil 245 mg én gang daglig 
Tenofovir disoproxil 245 mg once daily
Telzir hører til i en gruppe af antiretroviral medicin, der kaldes proteasehæmmere. 
Telzir belongs to a group of anti-retroviral medicines called protease inhibitors.
Lad sprøjte og adapter ligge, således at disse er helt tørre før de skal anvendes igen. 
Let them dry completely before you use them again.
Se nedenstående tabel for doseringsanbefalinger til voksne. 
Please refer to the table below for the dosing recommendations in adults.
Ingen FPV/RTV interaktionsstudier. 
No FPV/RTV drug interaction studies.
Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i henhold til lokale retningslinier. 
Any unused medicinal product should be disposed of in accordance with local requirements.
I stedet for Telzir oral suspension: 
As an alternative to taking Telzir oral suspension:
Telzir findes også som 700 mg filmovertrukne tabletter. 
Telzir is also available as 700 mg film-coated tablets.
Sammenlignet med historiske data er eksponeringen af amprenavir uændret. 
Amprenavir exposure unchanged when compared to historical data.
 Hold kontakt med lægen og stop ikke med at tage Telzir, før lægen anbefaler det. 
→ Keep in touch with your doctor, and don't stop taking Telzir without your doctor's advice.
SELEKTIVE SEROTONINREUPTAKE-HÆMMERE (SSRI'er) 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
Amprenavir hæmmer endvidere CYP3A4-enzymet, dog i mindre omfang end ritonavir. 
Amprenavir in addition is also an inhibitor of the CYP3A4 enzyme, although to a lesser extent than ritonavir.
• en kombination af lopinavir/ritonavir (mod hiv-infektion) 
• lopinavir/ritonavir combination (used to treat HIV infection)
Magnesiumstearat Kolloid vandfri silica 
Magnesium stearate Colloidal anhydrous silica
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton and the bottle.
Den gennemsnitlige laveste steady state amprenavir-plasmakoncentration (Cmin) var 2,12 (1,772,54) g/ml, og AUC0-tau var 39,6 (34,5-45,3)h·g/ml. 
The mean steady state plasma amprenavir trough concentration (Cmin) was 2.12 (1.77-2.54) µg/ml and AUC0-tau was 39.6 (34.5-45.3) h*µg/ml.
Tabel 3 Effektresultat ved uge 48 i APV30003 ITT(E)-populationen (patienter, der tidligere har fået antiviral behandling) 
Table 3 Efficacy at Week 48 Outcomes in APV30003 ITT(E) Population (ART-experienced Patients)
Kontraindiceret (se pkt. 
Contraindicated (see section
Effekten af Telzir kan være nedsat på grund af fald i plasmakoncentrationen af amprenavir hos patienter, som tager disse lægemidler (se pkt. 
Telzir may be less effective due to decreased amprenavir plasma concentrations in patients taking these medicinal products concomitantly (see section 4.5).
Doseringsanbefalinger for Telzir i kombination med ritonavir 
Dosing recommendations for Telzir with ritonavir Age
Medmindre andet er angivet, er studierne nedenfor udført med den anbefalede dosis af fosamprenavir (FPV)/ritonavir (RTV) (dvs. 700/100 mg 2 gange daglig), og interaktionen blev vurderet under steadystate-forhold, efter lægemidlerne var administreret i 10 til 21 dage. 
Unless otherwise stated, studies detailed below have been performed with the recommended dosage of fosamprenavir/ritonavir (i.e. 700/100 mg twice daily), and the interaction was assessed under steadystate conditions where drugs were administered for 10 to 21 days.
Fosamprenavir indeholder en sulfonamid. 
Fosamprenavir contains a sulphonamide moiety.
Ritonavir AUC12  0,66 Ritonavir Cmax  0,61 
Ritonavir AUC12 ↓ 0.66 Ritonavir Cmax ↓ 0.61 Ritonavir C12 ↔ 0.86
Overførelse af amprenavir via placenta har vist sig at forekomme hos mennesker. 
Placental transfer of amprenavir has been shown to occur in humans.
(Telzir 1.400 mg 2 gange daglig) 
(Telzir 1400 mg twice daily)
Baseline karakteristika ART/PI status, n (%) ART-naive Patienter der tidligere har fået antiretroviral behandling, PI-naive Patienter der tidligere har fået proteasehæmmere, PI-erfarne Median varighed af tidligere ART-eksponering, uger NRTI PI Median plasma hiv-1 RNA log10 kopier/ml 
Baseline Characteristics ART/PI status, n (%) ART-naïve ART-experienced, PI-naïve PI-experienced Median duration of prior ART exposure, weeks NRTI PI Median plasma HIV-1 RNA log10 copies/mL
Børn og unge bør tage fosamprenavir oral suspension sammen med mad. 
In children and adolescents the fosamprenavir oral suspension should be taken with food.
Samtidig administration af Telzir 700 mg 2 gange daglig og ritonavir i doser større end 100 mg 2 gange daglig er ikke blevet klinisk undersøgt. 
Co-administration of Telzir 700 mg twice daily with ritonavir in doses greater than 100 mg twice daily has not been clinically evaluated.
Overordnet kan, selv med ovennævnte dosisjusteringer til voksne med nedsat leverfunktion, nogle patienter have en højere eller lavere amprenavir- og/eller ritonavirkoncentration i plasma end forventet i forhold til patienter med normal leverfunktion pga. øget inter-individuel variation (se pkt. 
Overall, even with these dose adjustments for adults with hepatic impairment, some patients may have higher or lower than anticipated amprenavir and/or ritonavir plasma concentrations as compared to patients with normal hepatic function, due to increased inter-patient variability (see section 5.2), therefore close monitoring of safety and virologic response is warranted.
Geometrisk middelændring 
Geometric mean change
Fosamprenavir tabletter og oral suspension administreret med ritonavir og kombineret med NRTI'er er blevet evalueret hos proteasehæmmernaive børn og unge, samt hos børn og unge, der tidligere er behandlet med proteasehæmmere. 
Fosamprenavir tablets and oral suspension with ritonavir in combination with NRTIs have been evaluated in protease inhibitor naïve and experienced children and adolescent patients.
Læs indlægssedlen inden brug 
Oral use Read the package leaflet before use
Lægemidler, som inducerer, hæmmer eller er substrater for CYP3A4, skal derfor bruges med forsigtighed, hvis de skal gives sammen med Telzir og ritonavir (se pkt. 
Therefore medicinal products that are inducers, inhibitors or substrates of CYP3A4 must be used with caution when administered concurrently with Telzir with ritonavir (see sections 4.3 and 4.5).
Det frarådes at tage følgende medicin sammen med Telzir/ritonavir: 
These medicines are not recommended with Telzir/ritonavir:
APVs geometriske middelværdi (95 % konfidensinterval) og Ctau-værdier var 1,31 (0,97; 1,77), 1,34 (0,95; 1,89) og 2,03 (1,46; 2,83) μg/ml for henholdsvis andet trimester, tredje trimester og post partum og inden for intervallet af værdier hos ikke-gravide patienter på de samme behandlingsregimer med FPV/RTV. 
APV geometric mean (95% CI) and Ctau values were 1.31 (0.97, 1.77), 1.34 (0.95, 1.89), and 2.03 (1.46, 2.83) µg/mL for the second trimester, third trimester, and postpartum, respectively and within the range of values in non-pregnant patients on the same FPV/RTV containing regimens.
Derfor kan lægemidler, som har samme metaboliseringsvej eller modificerer aktiviteten af CYP3A4, muligvis ændre farmakokinetikken af amprenavir og ritonavir. 
Therefore, any medicinal products that either share this metabolic pathway or modify CYP3A4 activity may modify the pharmacokinetics of amprenavir and ritonavir.
25-O-desacetylrifabutin: AUC(0-48)  11-fold* *sammenlignet med rifabutin 300 mg én gang daglig 
25-O-desacetylrifabutin: AUC(0-48) ↑ 11-fold* *compared to rifabutin 300 mg once daily
Påvirkningen af p-ritonavir ved høje systemiske fluticasonkoncentrationer kendes ikke. 
The effects of high fluticasone systemic exposure on ritonavir plasma levels are unknown.
Administration af fosamprenavir tabletter efter fødeindtagelse (standardiseret meget fedtholdigt måltid: 967 kcal, 67 gram fedt, 33 gram protein, 58 gram kulhydrat) ændrede ikke på plasma amprenavir farmakokinetikken (Cmax, Tmax eller AUC0-) sammenlignet med administration under faste. 
Administration of the fosamprenavir tablet formulation in the fed state (standardised high fat meal: 967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate) did not alter plasma amprenavir pharmacokinetics (Cmax, tmax or AUC0-∞) compared to the administration of this formulation in the fasted state.
Amprenavir metaboliseres hovedsageligt i leveren, og mindre end 1 % udskilles uomdannet i urinen. 
Amprenavir is primarily metabolised by the liver with less than 1 % excreted unchanged in the urine.
Administration af fosamprenavir oral suspension sammen med et meget fedtholdigt måltid (967 kcal, 67 gram fedt, 33 gram protein, 58 gram kulhydrat) reducerede plasma amprenavir AUC(0-) med 28 % og Cmax med 46 % og forsinkede Tmax med 0,72 timer. 
Administration of the fosamprenavir oral suspension formulation with a high fat meal (967 kcal, 67 grams fat, 33 grams protein, 58 grams carbohydrate) reduced plasma amprenavir AUC(0-∞) by 28% and Cmax by 46% and delayed Tmax by 0.72 hours.
Bivirkningsprofilen var ens i alle de respektive studier med voksne: behandlingsnaive patienter (APV30002, ESS100732) og patienter, der tidligere har været behandlet med proteasehæmmere (dosering 2 gange daglig, APV30003). 
The adverse reaction profile was similar across all the respective adult studies: antiretroviral naïve patients (APV30002, ESS100732), protease inhibitor experienced (twice daily dosing, APV30003) patients.
Hvis du får et eller flere af disse symptomer:  Fortæl det til lægen. 
If you notice any of these symptoms: →Tell your doctor.
Når antineoplastiske midler, der metaboliseres af CYP3A, administreres samtidigt med fosamprenavir/ritonavir, kan plasmakoncentrationerne af disse antineoplastiske lægemidler øges og kunne øge risikoen for bivirkninger, der normalt er forbundet med disse antineoplastiske midler. 
When antineoplastic agents that are metabolised by CYP3A are co-administered with fosamprenavir/ritonavir, plasma concentrations of these antineoplastic medications may be increased and could increase the risk of adverse events usually associated with these antineoplastic agents.
Telzir 700 mg filmovertrukne tabletter Fosamprenavir 
Telzir 700 mg film-coated tablets Fosamprenavir
Kan resultere i en øget risiko for PDE5-hæmmerassocierede bivirkninger, herunder hypotension, synsændringer og priapisme (se produktinformationen for PDE5hæmmer). 
It may result in an increase in PDE5 inhibitor-associated adverse reactions, including hypotension, visual changes and priapism (refer to PDE5 inhibitor prescribing information).
Kan forårsage alvorlige bivirkninger (se pkt. 
It may cause serious adverse reactions (see section 4.4).
Ketoconazol 200 mg en gang daglig i 4 dage 
Ketoconazole 200 mg once daily for four days
Ketoconazol: Cmax  25 % Ketoconazol: AUC  2,69 fold. 
Ketoconazole: Cmax ↑ 25% Ketoconazole: AUC ↑ 2.69fold.
Ingen FPV/RTV interaktionsstudier dasatinib:  forventet nilotinib:  forventet ibrutinib:  forventet vinblastin:  forventet everolimus:  forventet (CYP3A4 hæmning) 
No FPV/RTV drug interaction studies dasatinib: ↑ expected nilotinib: ↑ expected ibrutinib: ↑ expected vinblastine: ↑ expected everolimus: ↑ expected (CYP3A4 inhibition)
Alle patienter i dette studie havde tidligere oplevet behandlingssvigt på et proteasehæmmerregime (defineret som plasma hiv-1-RNA som aldrig kom under 1.000 kopier/ml efter mindst 12 konsekutive ugers behandling, eller som initial suppression af hiv-1-RNA med efterfølgende rebound til  1.000 kopier/ml). 
All patients in this study had failed treatment with a previous protease inhibitor regimen (defined as plasma HIV-1 RNA that never went below 1,000 copies/ml after at least 12 consecutive weeks of therapy, or initial suppression of HIV-1 RNA which subsequently rebounded to ≥ 1,000 copies/ml).
Samtidig administration af Telzir og simvastatin eller lovastatin er kontraindiceret pga. øgede plasmakoncentrationer af simvastatin og lovastatin, hvilket kan øge risikoen for myopati, herunder rabdomyolyse (se pkt. 
Concomitant use of Telzir with simvastatin or lovastatin is contraindicated because of increased plasma concentrations of lovastatin and simvastatin which can increase the risk of myopathy, including rhabdomyolysis (see section 4.5).
Alvorlige proteasemutationer opstået under behandling eller APV-forbundet blev set i virus isoleret fra 2 patienter. 
Treatment-emergent major or APV-associated protease mutations were observed in virus isolated from 2 patients.
> 100.000 kopier/ml 
>100,000 copies/ml, n (%)
Signifikant nedsat amprenavir Cmin er observeret, hvilket kan medføre virologisk svigt hos nogle patienter. 
Significant reductions in amprenavir Cmin observed may result in virological failure in patients.
Børn kan tage voksendosis af ritonavir kapsler (100 mg 2 gange daglig), hvis de vejer mindst 33 kg og kan sluge kapslerne hele. 
Children can take the adult dose of ritonavir capsules (100 mg twice daily) if they weigh at least 33 kg and can swallow the capsules whole.
Lægen vil afgøre, om medicinen kan tages sammen med Telzir og ritonavir. 
Your doctor will decide if these medicines are suitable for you to take with Telzir and ritonavir.
Autoimmune sygdomme (som f.eks. Graves´ sygdom og autoimmun hepatitis) er også blevet rapporteret i forbindelse med immunreaktivering; dog er den rapporterede tid til frembrud mere variabel, og frembrud kan forekomme mange måneder efter behandlingsstart (se pkt. 
Autoimmune disorders (such as Graves' disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Lovastatin:  forventet 
Lovastatin: ↑ expected Simvastatin: ↑ expected
Mekanismen for denne interaktion er CYP3A4hæmning af fosamprenavir/ritonavir. 
mechanism of interaction is CYP3A4 inhibition by fosamprenavir/ritonavir.
Telzir i kombination med en lav dosis ritonavir er indiceret til behandling af hiv-1-inficerede voksne, unge og børn over 6 år i kombination med andre antiretrovirale lægemidler. 
Telzir in combination with low dose ritonavir is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products.
CD4-celletal < 50 
All Patients CD4-count <50
En 10 ml doseringssprøjte og en adapter er vedlagt i pakningen 
A 10 ml graduated dosing syringe and an adapter are also included in the pack.
Produktresumeet for ritonavir skal derfor læses før påbegyndelse af behandlingen med Telzir. 
The Summary of Product Characteristics of ritonavir must therefore be consulted prior to initiation of therapy with Telzir.
Lægen vil måle dit blodsukker, inden du begynder behandling med Telzir og løbende, mens du er i behandling. 
Your doctor will monitor your blood glucose levels before and during treatment with Telzir.
ALFA1-ANTAGONISTER Alfuzosin 
ADRENORECEPTOR ANTAGONIST Alfuzosin,
700 mg (1 tablet eller 14 ml suspension) 
Tablet or Oral suspension 700 mg (1 tablet or 14 ml suspension)
(RTV inducerer og/eller hæmmer CYP2C9) 
(Induction and/or inhibition of CYP2C9 by RTV)
Børn, som vejer mindre end 39 kg, bør anvende Telzir oral suspension, idet den nøjagtige dosering til denne patientgruppe baseres på kropsvægt (se i produktresuméet for Telzir oral suspension). 
For children weighing less than 39 kg, Telzir oral suspension is the recommended option for the most accurate dosing in children based on body weight (please refer to the Summary of Product Characteristics for Telzir oral suspension).